

Performance

31 March 2019

In 2016 I started a new approach, called “Intelligent Cloning” and I will continue using this approach probably for many, many years and I will optimize it, if necessary, as I move forward.

A “cloneable” is an investment idea of an exceptional investment manager, that is within your circle of competence and is trading at an attractive price. The price you want to pay depends on the certainty of the future cash flow streams of the company, in the light of the current interest rate environment. And I will only invest in such an opportunity if I am able to look through the company into its future and see, almost smell, this long term trajectory of value creation, or profitable growth, if you wish.

Current positions


When	Company	Price	Return
2H '16	Deere	87 USD	90,3 %
2H '16	Allison Transmission	29 USD	59,6 %
1H '17	Davita	65 USD	(16,5 %)
1H '17	Verisign	83 USD	118,7 %
2H '17	Monro	47 USD	86,4 %
1H '18	Sinclair Broadcast	30 USD	29,5 %
2H '18	StoneCo	17 USD	141,8 %
2H '18	Veritiv	24 USD	9,7 %
1H '19	Liberty Global	22 USD	13,3 %

Closed positions

When	Company	Price	Sold	Return
2H '17	Tegna	13 USD	2H '18	2,7 %
1H '18	Esterline Corp.	72 USD	2H '18	69,5 %

These are not actual fund results, but it illustrates what the results could have been if we indeed started an investment partnership in 2H '16. The stocks are selected with the idea to hold on to these companies for many, many years. Preferably decades, as long as the company remains a good company.

Just as important as picking the right company to invest in, is using the downturns of the markets. StoneCo, Veritiv and Liberty Global were added to this portfolio just after the 20% market correction from its 52 week high.



In 2H '18, I sold both Tegna @13 USD and Esterline Corporation @122 USD. The rationale behind selling Tegna is that David Einhorn sold the stock, so there is no backing any more from one or more superinvestors I admire. The rationale behind selling Esterline Corporation is that TransDigm announced to acquire Esterline for \$122.50 per share in cash.

Disclaimer

This presentation and the information contained herein are for educational and informational purposes only and do not constitute, and should not be construed as, an offer to sell, or a solicitation of an offer to buy, any securities or related financial instruments. Responses to any inquiry that may involve the rendering of personalized investment advice or effecting or attempting to effect transactions in securities will not be made absent compliance with applicable laws or regulations (including broker dealer, investment adviser or applicable agent or representative registration requirements), or applicable exemptions or exclusions therefrom. The Value Firm® makes no representation, and it should not be assumed, that past investment performance is an indication of future results. Moreover, wherever there is the potential for profit there is also the possibility of loss.

Everybody makes mistakes now and then. If you find any, let me know: peter@thevaluefirm.com. Always do your own research.